Celcuity Reports Improved Progression-Free Survival with Revtorpyk in Phase 3 Breast Cancer Trial
Celcuity has announced updated results from its phase 3 VIKTORIA-1 clinical trial, demonstrating that the combination of Revtorpyk (gedatolisib), fulvestrant, and Pfizer's Ibrance (palbociclib) significantly improved median progression-free survival in patients with breast cancer. The study compared this regimen against a control group receiving Novartis' Vijoice. The positive data from the VIKTORIA-1 cohort suggests that Revtorpyk could become a potent component of treatment regimens for advanced breast cancer. This development is significant for Celcuity as it advances its lead candidate toward potential regulatory approval and market entry.
